For the latest COVID-19 Travel restrictions and recommendations please click here

SMi's premier 11th Annual Parallel Trade for Pharma returns to London on 6-7 Feb 2017 after 10 successful years in the running!

According to the European Federation of Pharmaceutical Industries and Associations, parallel trade was estimated to amount to € 5,589 million (value at ex–factory prices) in 2014. The fragmentation of the EU pharmaceutical market has resulted in a lucrative year for parallel trade.  Factors such as foreign exchange fluctuations and  legal battles on trademarks and counterfeit medicines are continuously shifting the European market dynamics.

With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? This event will discuss short term versus long term concerns of pharma manufacturers, regulators, as well as parallel traders. They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges. Discussion topics include:

  • Parallel Trade 101 - Which factors determine the flow of pharmaceutical products in Europe?
  • The European Commission’s Falsified Medicines Directive – recent updates
  • Panel Debate – In the spotlight: Shortages
  • The Patient’s perspective
  • Parallel traders panel – challenges and opportunities
  • Beyond pharmaceutical products – parallel imports of medical devices
  • Panel Debate - In the spotlight: Technology & new trends
  • Regional and country focus - Scandinavia, Germany, the UK, Central and  Eastern Europe, Turkey and Eurasia

This is the only industry meeting with 80+ selected senior leaders in parallel trade to discuss upcoming trends and share best practices. Join us today to keep abreast and stay ahead of competition!

This conference will enable you to:
•Update on parallel trade regulations to ensure compliance
•Recap on regional markets' parallel trade activities and outlooks
•Reassess and benchmark your supply chain and distribution model against peers' for best practice
•Understand the rationale and strategy of parallel distributors through case studies and panel discussions
•Network and interact with senior thought leaders to discuss common challenges and share experiences

Who Should Attend?

VPs, Directors, Heads, Chiefs, Principals, Managers of:
Parallel Trade/ Import/ Export
Supply Chain Management/ Planning
General Counsel
Market Access
Business Planning
Regulatory/ Public Affairs

from pharmaceutical and biotechs, drug manufacturers, pharmaceutical wholesalers, pharmacies, pharmaceutical importers and exporters, parallel traders, medical device, regulator and academics.


Abbott Laboratories Limited; Agency for Medicinal Products and Medical Devices of the Republic of Slovenia; Allergan Limited; Amgen; Amgen; Arnold and Porter; Astellas Pharma Europe; AstraZeneca; Bayer Healthcare; Biogen Idec; Biopharm Insight; Boehringer-Ingelheim; Bulmar ML Ltd; Chiesi Farmaceutici SpA; Delfarma; EY; Europe Economics; European Alliance for Access to Safe Medicines; European Association of Euro-Pharmaceutical Companies; Galderma; German Pharmaceutical Industry Association; Gilead Sciences Ltd; Grunenthal Gmbh; IGES Institut.; IMS Health; Kantar Health; LEO Pharma A/S; McKesson Global Procurement & Sourcing Limited; McKesson Pharmaceutical; MD Pharma SA; Merck Sharp and Dohme Israel; MHRA; MPA Business Services Ltd; MPCC Global Regulatory Solutions; Mundipharma ;NOVARTIS; Novo Nordisk Pharma AG; Otsuka Pharmaceutical Europe Ltd; Preglem/ Gedeon Richter; Quintiles (UK) Ltd; Ratiopharm GmbH; Sanofi Pasteur MSD; Shire Pharmaceuticals Group Plc; Smith & Nephew; Teva Pharmaceuticals Europe BV; The National Pharmaceutical Association Ltd; UCB Pharma and many more!

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Heinz Kobelt

Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
View Bio

9:10 The European Commission’s Falsified Medicines Directive – recent updates

Richard Greville

Richard Greville, Director Wales and Director Distribution & Supply, The Association of the British Pharmaceutical Industry
View Bio

  • Exploring the legal framework of the Falsified Medicines Directive
  • What progress has been made since February 2016?
  • Implementation of the Falsified Medicines Directive - the new rules on medicine verification
  • All what you need to know about  "product information templates”
  • What are the regulatory requirements for nationally authorised products?
  • 9:50 Initiatives of Parallel Distributors in the context of Falsified Medicines Directive

    Flemming  Wagner

    Flemming Wagner, CEO, Abacus Medicine

  • Good Parallel Distribution Guidelines
  • Early Warning Anti-CF Platform
  • Joint Audits Initiative
  • European Medicines Verification Organization
  • 10:30 Morning Coffee

    11:00 European Medicines Verification Organization – an update from Brussels

    Heinz Kobelt

    Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
    View Bio

  • Explaining the complexity behind the planning and design of a pan-European medicine verification system
  • Implementing national verification systems that function at an equal level of efficacy, are interoperable and cost effective
  • The role of the European Hub and national data repositories
  • EMVO and interactions with various supply chain stakeholders
  • 11:40 Panel Debate – In the spotlight: Shortages

  • Shortages explained – manufacturing and trade related shortages
  • The implications of parallel trade for low-price countries
  • When Governments need to intervene – Bulgaria’s case – oncology drugs
  • Examining an increased tendency to yield new medicines’ availability in low income countries
  • Overcoming the challenges – on the road to a more transparent and regulated distribution cycle
  • Will new potential trade barriers eliminate the shortages problem?
  • Impact of possible import of products from outside the EU into the EU
  • Oliver Luksic

    Oliver Luksic, Head of Government Affairs , European Association of Euro-Pharmaceutical Companies
    View Bio

    Flemming  Wagner

    Flemming Wagner, CEO, Abacus Medicine

    Ladislav Holocsi

    Ladislav Holocsi, Apps Project Manager, Pharm-in

    12:20 Networking Lunch

    13:30 Which categories of pharmaceutical products offer highest margins for traders? What is a good profit margin?

    Ladislav Holocsi

    Ladislav Holocsi, Apps Project Manager, Pharm-in

    • Regional outlook – product range vs. product value for parallel trade in Europe

    • The increasingly diversified product portfolio for parallel distribution – challenges and opportunities

    • Which categories of products are favoured by parallel distributors?

    14:10 Northern Europe – opportunities and challenges

    Sigve Sivertsen

    Sigve Sivertsen, Head of Parallel Trade, Apotek Hjärtat
    View Bio

  • An overview of latest developments in parallel trade in Northern Europe (including Scandinavia)
  • Parallel trade – what does the future hold?
  •  The benefits of parallel trade for the European society
  • Future threats to parallel trade
  • 14:50 Afternoon Tea

    15:20 Region focus: Eurasia

    Alexey Savin

    Alexey Savin, Principal Russia and CIS, QuintilesIMS

  • Exploring regulatory aspects in Eurasia
  • Focus on Russia – reviewing the status after the recent legalisation of parallel trade
  • Azerbaijan as a regional hub
  • 16:00 Legal 101 - IP, competition and regulatory law

  • The impact of IP on parallel trade of pharmaceuticals
  • The competition restrictions on dual pricing, quota and DTP models
  •  How does the regulatory system deal with parallel trade?
  • Tim Frazer

    Tim Frazer, Partner and Head of London office, Arnold & Porter Kaye Scholer

    Christopher Stothers

    Christopher Stothers, Partner, Arnold & Porter Kaye Scholer LLP

    16:40 Chairman's Closing Remarks and Close of Day One

    9:00 Chairman's Opening Remarks

    Mike Isles

    Mike Isles, Executive Director, European Alliance for Access to Safe Medicines
    View Bio

    9:10 European parallel trade – past, present and future

    Shabnam Hanassab

    Shabnam Hanassab, Engagement Manager, QuintilesIMS
    View Bio

  • Key trends and dynamics in distribution and dispensing
  • Outlook and key factors likely to influence the market going forward
  • 9:50 The case against parallel trade in the EU – will the UK end parallel trade

  • Patented pharmaceuticals are not like widgets
  • Parallel trade is wasteful and does no good
  • Parallel trade prevents poor people from being treated with the best medicines
  • Iona McCall

    Iona McCall, Managing Consultant, Europe Economics
    View Bio

    10:30 Morning Coffee

    11:00 Fighting fakes by raising public awareness – how to change consumer behaviours

    Mike Isles

    Mike Isles, Executive Director, European Alliance for Access to Safe Medicines
    View Bio

  • An overview of statistical trends and the rising threat
  • What are the most efficient ways to address the safety and legitimacy of websites selling medicines
  • The power of educational websites – convincing results that raising consumer awareness can change behaviours
  • What organisations actively collaborate to enhance patient safety and how can you get involved
  • 11:40 Parallel traders panel – challenges and opportunities

  • How traders can work together to improve supply chain safety – unleashing the potential of collaboration
  • Strategies for overcoming the threat to patients posed by counterfeit drugs - the role of traders in ensuring product quality and safety
  • An overview of initiatives in the context of Falsified Medicines Directive
  • Flemming  Wagner

    Flemming Wagner, CEO, Abacus Medicine

    Sigve Sivertsen

    Sigve Sivertsen, Head of Parallel Trade, Apotek Hjärtat
    View Bio

    12:20 Networking Lunch

    13:40 Interpreting the Specific Mechanism- importation from Accession states

    Martin Paltnoi

    Martin Paltnoi, Managing Director, MPA Business Services Ltd

    • Break down of the Accession Treaty and how it is ensures the transfer of IP rights from destination state to the country of origin
    • The growing need to further specify accession treaty and the ways in which one can interpret it
    • The Specific Mechanism relating to the Accession Treaties will eventually dissipate, but not until it has caused a great deal of discomfort for both the importer and those whose products are being imported- what are the strategies to deal with this?

    14:20 Managed entry schemes, HTA and parallel trade

    Andrew Stainthorpe

    Andrew Stainthorpe, Director Market Access and Managed Entry, Research Health

  • Managed entry arrangements are becoming the norm for high cost drugs
  • How schemes are tailored to each market -  including national, regional and local arrangements
  • Significant price differences and the potential for parallel trading
  • Exploring available mechanisms to address risks
  • 15:00 Chairman’s Closing Remarks and Close of Day Two



    Flemming  Wagner

    Flemming Wagner

    CEO, Abacus Medicine
    Heinz Kobelt

    Heinz Kobelt

    Director European Affairs, European Association of Euro-Pharmaceutical Companies
    Mike Isles

    Mike Isles

    Executive Director, European Alliance for Access to Safe Medicines
    Richard Greville

    Richard Greville

    Director Wales and Director Distribution & Supply, The Association of the British Pharmaceutical Industry
    Shabnam Hanassab

    Shabnam Hanassab

    Engagement Manager, QuintilesIMS

    Alexey Savin

    Principal Russia and CIS, QuintilesIMS
    Alexey Savin

    Andrew Stainthorpe

    Director Market Access and Managed Entry, Research Health
    Andrew Stainthorpe

    Christopher Stothers

    Partner, Arnold & Porter Kaye Scholer LLP
    Christopher Stothers

    Flemming Wagner

    CEO, Abacus Medicine
    Flemming  Wagner

    Heinz Kobelt

    Director European Affairs, European Association of Euro-Pharmaceutical Companies
    Heinz Kobelt

    Heinz Kobelt, holds the position of Director European Affairs of the EAEPC after having served as its Secretary General from February 2005 to April 2011.
    The European Association of Euro-Pharmaceutical Companies (EAEPC) is the representative voice of pharmaceutical parallel distribution in Europe. Through national association or individual company membership it encompasses some 88 firms from 23 countries in the European Economic Area (EEA).
    Before that, from 2001-2003, Heinz Kobelt was Head European Government Affairs of Novartis International, located in Brussels.
    From 1990 – 2001, Heinz Kobelt worked as an international public servant in the Secretariat of the European Free Trade Association (EFTA), where he participated in the negotiations of the EEA Agreement and held various positions as economist and policy analyst. He was stationed in Geneva, and from 1992 in Brussels.
    Between 1977 and 1990, he was a member of the Economics Administration of the Swiss Canton of St. Gallen, responsible for economic development and investment promotion.
    Heinz Kobelt holds a degree in economics (Dr. oec) from the University of St. Gallen, Switzerland.

    Iona McCall

    Managing Consultant, Europe Economics
    Iona McCall

    <p>Iona McCall is a Managing Consultant with over 14 years as a professional economist. Iona is a specialist competition economist with strong industrial organisation and competition policy experience. Iona also has extensive experience in estimating consumer welfare effects created by a changes in firm behaviour and market structure.<br /> Iona&rsquo;s experience covers a broad range of sectors including health and pharmaceuticals. She has worked on projects for Monitor, the Department of Health and the European Commission, as well as private clients. Her recent experience in this area includes an evaluation of the clinical trial process in the UK and review of international best practice, and a study to explore the way in which prices are formed in healthcare markets across the EU.<br /> Prior to joining Europe Economics, Iona spent over five years working as an economist in the Government Economic Service. She holds an MSc in Economics from the London School of Economics and a BSc (first class) in Economics and French from the University of Birmingham.<br /> Iona is a Member of the Association of Competition Economics (ACE) and has published articles in Competition Law Insight.</p>

    Kathy Osgerby

    Associate, Arnold & Porter Kaye Scholer LLP
    Kathy Osgerby

    Kathy Osgerby is an Associate in the IP team at Arnold & Porter in London. She advises clients on contentious intellectual property matters and has extensive experience in the life sciences industry. She advises clients on the full range of IP issues including trade mark enforcement, parallel trade and exhaustion of rights. Kathy has a degree in Molecular Biology and Biochemistry, studied intellectual property law at a postgraduate level, and is a qualified solicitor advocate.

    Ladislav Holocsi

    Apps Project Manager, Pharm-in
    Ladislav Holocsi

    Martin Paltnoi

    Managing Director, MPA Business Services Ltd
    Martin Paltnoi

    Mike Isles

    Executive Director, European Alliance for Access to Safe Medicines
    Mike Isles

    Mike is Executive Director of the European Alliance for Access to Safe Medicines (EAASM). The EAASM is a pan-European patient safety organisation, bringing together all concerned with eliminating falsified medicines from the supply chain.
    With patient safety at its heart, the EAASM is also currently championing positive change in the area of unlicensed/off-label usage of medicines which is severely compromising patient’s welfare and rights in certain medical conditions and situations.
    Mike is also the Executive Director of the Alliance for Safe Online Pharmacy in the EU (ASOP EU). With over 30,000 fake pharmacy websites targeting Europe on any given day, this multisectoral organisation’s mission is to enable patients to buy their medicines online safely – where it is legal to do so. With over 50 participants involving many key Internet stakeholders, its aim is to produce concrete voluntary actions that will make a real difference and ultimately benefit the health of patients and the wealth of nations.
    Mike is also European Medicines Partnership Director for International Health Partners a UK charity whose Queen’s Award for Enterprise for continuous Innovation in 2011, recognises the tremendous humanitarian work sourcing donated quality medicines from the pharmaceutical industry and coordinating delivery via secure supply chain solutions to disaster-struck areas in close liaison with NGOs. In December 2014, hosted by the Patron of IHP, HRH The Prince of Wales, a new initiative called EURMED was launched by three leading European medical NGOs (action medeor, Banco Farmaceutico and International Health Partners), with the shared objective of ensuring the efficient and effective use of product donations from the European healthcare industry to address the needs of underserved communities around the world.
    Mike’s professional background is in pharmaceuticals, where he held senior management and director positions covering sales, marketing, commercial and supply chain in a 32-year career.

    Oliver Luksic

    Head of Government Affairs , European Association of Euro-Pharmaceutical Companies
    Oliver Luksic

    School Background

    2004- 2006 European affairs and Economics at the Grande École IEP in Paris (“Sciences Po”)
    Degree: Master
    2003 - 2004 European and war studies at King’s College London
    2001 - 2006 Institut d’études politiques de Paris in Nancy
    2000 - 2001 Civil service at Heusweiler Welfare Centre
    1991 - 2000 German-French academic secondary school in Saarbrücken
    Degree: Abitur (higher-education entrance qualification) and baccalauréat

    Career progression

    Since 2016 Head of government affairs EAEPC
    2014-2016 Consultant / Director European affairs Kohlpharma
    2012/2013 Spokesman on transport policy for the FDP parliamentary group
    2009-2013 Member of the German Bundestag
    Member in the Committee on Transport, Building and Urban Development of the German Bundestag
    Member in the Committee on the Affairs of the European Union in the German Bundestag
    2006 - 2009 Consultant

    Place of birth: Saarbrücken
    marital status: married, two kids

    Richard Greville

    Director Wales and Director Distribution & Supply, The Association of the British Pharmaceutical Industry
    Richard Greville

    Dr Richard Greville is an ABPI Director with responsibility for Wales and the Distribution & Supply Chain.
    He was initially appointed to the post of Director of ABPI Cymru Wales in May 2003 after serving an apprenticeship of 15 years in a wide range of roles within the pharmaceutical industry. Over the years Richard has also held ABPI Director responsibility for Northern Ireland and International Affairs, representing the ABPI strategically at both the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
    Since April 2014 Richard has combined his continuing ABPI responsibility for Wales with that for the UK Distribution and Supply Chain, including homecare, procurement, the Falsified Medicines Directive and supply chain shortages.
    He holds a Board position on the National Research Network for Life Sciences and Health (Wales). He is also a member of the Welsh Governments Division for Social Care and Health Research (DSCHR) Stakeholder Strategy Group and the Advisory Boards of the Diabetes Diploma at the University of South Wales and the Wales Cancer Bank. Richard is a founding Director of SecurMed UK, the UK medicines verification organization.

    Shabnam Hanassab

    Engagement Manager, QuintilesIMS
    Shabnam Hanassab

    IMS Health’s expert and thought leader in European Parallel Trade dynamics, supply chain and distribution with years of experience working in this field. Shabnam has developed in-depth expertise in pharmaceutical market dynamics and the increasing complexities of the trading environment. Shabnam is highly experienced on IMS Health’s data types, coverage and various supply chain offerings available centrally as well as locally, working with network of people within and outside organization. She has led several European supply chain consulting projects in the past few years.
    Shabnam holds BSc, MSc and PhD from University of London in Pharmaceutical and Computational Chemistry.

    Sigve Sivertsen

    Head of Parallel Trade, Apotek Hjärtat
    Sigve Sivertsen

    Sigve Sivertsen has 18 years of experience in parallel trade. Started in the Norwegian market in 1999 at Apotek 1 which later was a part of the Phoenix group and was involved in the deregulation of the Norwegian pharmacy market in March 2001, also responsible for building up the Rx department which also included our own parallel trade.
    Moved to Sweden in 2010 and was assigned to Apotek Hjärtat to build up the parallel trade department to meet the requirement according to the deregulation of the market which was in 2009. Involved to build up Apotek Hjärtat own wholesaler and also head of negotiation with the PI supplier to move the goods to Apotek Hjärtat distribution centre.

    Tim Frazer

    Partner and Head of London office, Arnold & Porter Kaye Scholer
    Tim Frazer

    Official Media Partner



    Understanding IP and competition law issues in parallel trade

    Understanding IP and competition law issues in parallel trade

    Holiday Inn Kensington Forum
    8th February 2017
    London, United Kingdom

    Preliminary list of companies attending Parallel Trade 2017


    Interview with Eric Noehrenberg, Director, Regional Market Access Lead, Latin America, Shire Pharmaceutical Ltd


    List of 2016 attendees


    Media Partners


    Official Media Partner

    A pioneer in the field, HealthEconomics.Com is the world’s most comprehensive and credible website for resources and jobs in healthcare value and market access. A trusted resource, HealthEconomics.Com contains the hottest news, jobs, policy updates, professional development, and education resources, and offers unparalleled advertising opportunities. As the #1 Google ranked website in health economics, HealthEconomics.Com attracts 11,000 visitors every month and the well-respected Newsletter reaches 20,000 professionals every week. The comprehensive content is carefully selected by a discerning health economist editor, making us the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

    Media Partners



    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

    Drug Discovery Today


    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    Pharmaceutical Outsourcing


    Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.



    FirstWord is an innovative industry intelligence leader serving over 200,000 Pharma Professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    International Journal of Technology, Policy and Management


    IJTPM is a refereed international journal that provides a professional and scholarly forum in the emerging field of decision making and problem solving in the integrated area of technology policy and management at the operational, organisational and public policy levels.



    Pharmaceutical-Tech : “In the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers. Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.”

    International Journal of Biomedical Engineering and Technology


    IJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).



    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

    Medical News Today


    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.

    American Pharmaceutical Review


    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy



    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.

    International Journal of Services and Standards


    IJSS presents current practice, models, and theory in both services and standards development, design, management, implementation, and applications. Its objectives are to develop, promote and coordinate the development and practice in services and standards.

    Swiss Biotech Association


    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    EIN News


    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.

    Drug Target Review


    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.

    International Journal of Biotechnology


    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

    BioPharm Insight


    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

    Contract Biotechnology


    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!

    International Journal of Healthcare Policy


    IJHP serves as a forum for interdisciplinary discussion of leading issues in healthcare law, medicine and health policy. Emphasis is placed on issues such as legislative and regulatory environments, and plans and actions that are undertaken by organisations and agencies to achieve specific healthcare goals within society. This perspective is reflective of the broad range of efforts to advance the public's health.



    International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

    Inderscience Publishers


    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.



    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

    Pharma Focus Asia


    Pharma Focus Asia is a bi-annual magazine from Ochre Media Pvt. Ltd. Pharma Focus Asia covers important issues and trends shaping the future of the Pharma industry across Asia and rest of the world. It is the leading Pharma title in print as well as digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies.



    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

    Select Science


    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out